secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001193125-22-307296
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma appoints Lynn Seely as President and CEO, succeeding Elizabeth Homans
--------------------------------------------------------------------------------

- Elizabeth Homans steps down as CEO effective Dec 15, 2022; will remain as consultant through June 2024.
- Homans receives $900k base salary severance (18 months), $360k target bonus, continued option vesting, COBRA.
- Lynn Seely appointed President and CEO; annual base salary $650k, target bonus 60%, and option for 7.5M shares.
- Seely previously CEO of Myovant Sciences and CMO of Medivation; joined Lyell Board in May 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/d438667d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-307296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer